Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34709929/

1 University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Germany. 2...

Optimizing autologous hematopoietic stem cell transplantation for acute leukemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34724713/

Autologous hematopoietic stem cell transplantation (ASCT) remains an important postremission treatment for acute leukemia (AL). It is known that some prognostic factors, such as age, cytogenetic and molecular risk stratification,...

Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34727819/

The major challenge in minimal residual disease ( MRD) detection is the antigen modulation in post treated samples restraining the use of diagnostic immunophenotypic (IP) signature of leukemic blasts for...

The road to personalized myeloma medicine: Patient-specific single-domain antibodies for anti-idiotypic radionuclide therapy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34667109/

Multiple myeloma remains to this day an incurable cancer. For many patients, recurrence is unavoidably a result of lacking treatment options in the minimal residual disease stage. This is due...

Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34679569/

Minimal residual disease (MRD) status is now considered as one of the most relevant prognostic factors in multiple myeloma (MM) while MRD negativity became an important endpoint in clinical trials....